SI-BONE, Inc. reported a 27% increase in worldwide revenue for Q4 2022, reaching $32.0 million. U.S. revenue increased by 28% to $30.0 million. The company's net loss was $11.2 million, or $0.32 per diluted share, and the adjusted EBITDA loss improved by 54% to $4.2 million.
Worldwide revenue increased by 27% to $32.0 million compared to the prior year period.
U.S. revenue grew by 28% to $30.0 million, driven by domestic case volumes.
Gross margin was 84%, impacted by lower average selling prices and higher costs.
Net loss improved to $11.2 million, or $0.32 per diluted share, compared to $14.5 million in the prior year period.
SI-BONE expects 2023 worldwide revenue of approximately $124 million to $127 million, representing growth of approximately 17% to 19% compared to fiscal year 2022. SI-BONE also anticipates that gross margin will be approximately 80% for fiscal year 2023 and Adjusted EBITDA loss will continue to improve year over year in 2023.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance